Atkinson K, Dodds A J, Concannon A J, Biggs J C
Department of Haematology, St Vincent's Hospital, Darlinghurst, NSW.
Med J Aust. 1987 Nov 16;147(10):510-2.
Since bone-marrow transplant recipients receive considerable quantities of packed-cell, platelet and sometimes leukocyte transfusions, as well as the donor marrow infusion, it would be predictable that acquired immunodeficiency syndrome (AIDS) by blood-product transfusion would occur in this patient population. We report here two patients who received HLA-identical sibling bone-marrow transplants for acute non-lymphoblastic leukaemia during their first remission. Both developed category-A AIDS at days 342 and 546 after transplantation, respectively. Neither patient belonged to any known high-risk group for AIDS, other than having received a blood-product transfusion. One of the two patients is now known to have received blood from a donor who was human immunodeficiency virus (HIV) seropositive. Both patients developed Pneumocystis carinii pneumonia and other opportunistic infections, and both have died of AIDS without evidence of recurrence of their leukaemia. One patient had no chronic graft-versus-host disease (GVHD) and the other had mild chronic GVHD of the mouth. Since severe opportunistic infections are rare after transplantation in the absence of GVHD, their late occurrence after transplantation should raise the suspicion of AIDS. This complication is likely to have an adverse impact on the long-term survival of patients who received bone-marrow transplants between 1981 and the introduction of effective screening tests for HIV infection in blood donors.
由于骨髓移植受者会接受大量的红细胞、血小板输血,有时还会接受白细胞输血以及供体骨髓输注,因此可以预测,该患者群体中会出现因输血导致的获得性免疫缺陷综合征(艾滋病)。我们在此报告两名在首次缓解期因急性非淋巴细胞白血病接受 HLA 相同的同胞骨髓移植的患者。两人分别在移植后第 342 天和第 546 天发展为 A 类艾滋病。除了接受过输血外,这两名患者均不属于任何已知的艾滋病高危群体。现已查明,两名患者中的一名接受了来自一名人类免疫缺陷病毒(HIV)血清阳性供体的血液。两名患者均患上了卡氏肺孢子虫肺炎和其他机会性感染,且均死于艾滋病,白血病无复发迹象。一名患者没有慢性移植物抗宿主病(GVHD),另一名患者有轻度口腔慢性 GVHD。由于在没有 GVHD 的情况下,移植后严重的机会性感染很少见,因此移植后晚期出现此类感染应引起对艾滋病的怀疑。这种并发症可能会对 1981 年至对献血者进行有效的 HIV 感染筛查试验引入之前接受骨髓移植的患者的长期生存产生不利影响。